Last reviewed · How we verify
Anti-VEGF (anti-vegf)
Anti-VEGF (generic name: anti-vegf) is a Anti-VEGF IV (bevacizumab) Monoclonal antibody drug developed by Pfizer Inc.. It is currently in discontinued development.
Anti-VEGF IV (bevacizumab)
Anti-VEGF agents, such as bevacizumab and aflibercept, are being studied in clinical trials for various prostate cancer stages, including adenocarcinoma of the prostate and recurrent prostate cancer. These agents are used to target a specific mechanism, but the exact modality of action is currently unknown.
At a glance
| Generic name | anti-vegf |
|---|---|
| Sponsor | Pfizer Inc. |
| Drug class | Anti-VEGF IV (bevacizumab) |
| Modality | Monoclonal antibody |
| Therapeutic area | Oncology |
| Phase | discontinued |
Mechanism of action
In certain eye diseases, the body mistakenly produces excessive amounts of a substance called VEGF (vascular endothelial growth factor). This substance acts like a chemical messenger that signals blood vessels to grow rapidly and abnormally. These new vessels are fragile, leak fluid, and cause scarring and vision loss. Anti-VEGF medications work by intercepting this chemical messenger before it can tell blood vessels to grow, essentially stopping the disease at its source. When anti-VEGF drugs are injected into the eye, they bind to and neutralize VEGF molecules circulating in the eye tissue. By removing this growth signal, the abnormal vessels either shrink or stop growing altogether. This prevents the leakage and inflammation that damage the light-sensitive cells in the retina, the part of the eye responsible for vision. The result is that many patients experience stabilized or improved vision, particularly when treated early. Different anti-VEGF medications work slightly differently—some are monoclonal antibodies that directly grab VEGF molecules, while others are smaller proteins that block VEGF receptors on blood vessel cells. Despite these differences, they all aim to achieve the same goal: reducing the abnormal blood vessel growth and preserving the patient's remaining eyesight.
Approved indications
Pipeline indications
- Gastrointestinal Tumors — discontinued
Common side effects
Key clinical trials
- A Trial Of CVX-060, An Anti-Angiogenic COVX-Body, In Combination With Sunitinib In Patients With Adv (Phase 2)
- PF-00299804 in Adult Patients With Relapsed/Recurrent Glioblastoma (Phase 2)
- A Phase 2, Multi-Center Study To Compare The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Anta (Phase 2)
- A Trial Of SU14813 In Patients With Advanced Solid Malignancies (Phase 1)
- A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Can (Phase 1/2)
- Study to Test the Safety and Tolerability of PF-07062119 in Patients With Selected Advanced or Metas (Phase 1)
- SU011248 Versus Interferon-Alfa As First-Line Systemic Therapy For Patients With Metastatic Renal Ce (Phase 3)
- Investigational Agent AG-013736 In Combinations With Standard Of Care Treatments For Patient's With (Phase 1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Anti-VEGF CI brief — competitive landscape report
- Anti-VEGF updates RSS · CI watch RSS
- Pfizer Inc. portfolio CI
Frequently asked questions about Anti-VEGF
What is Anti-VEGF?
How does Anti-VEGF work?
Who makes Anti-VEGF?
What is the generic name of Anti-VEGF?
What drug class is Anti-VEGF in?
What development phase is Anti-VEGF in?
Related
- Drug class: All Anti-VEGF IV (bevacizumab) drugs
- Manufacturer: Pfizer Inc. — full pipeline
- Therapeutic area: All drugs in Oncology
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing